The effect of pirenzepine on the growth hormone response to growth hormone-releasing hormone in obese children

S. Loche, M. Cappa, A. Faedda, C. Pintor

Research output: Contribution to journalArticle

Abstract

We studied the effect of pirenzepine, a cholinergic antagonist, on the GH response to GH-releasing hormone (GHRH) in 6 obese children (4 males and 2 females) aged 5.3-12.8 years with excess body weight ranging from 42 to 125% for their stature. A GHRH test was also performed in 8 short normal children (5 males and 3 females, age 6.8-11 years) studied as controls. In the obese patients two GHRH (GHRH 1-29, 1 μg/Kg iv) tests were performed 3-7 days apart in random order. Sixty min before the GHRH bolus the patients received placebo or pirenzepine (50 mg po). Mean peak and area under the curve (AUC) responses to GHRH were significantly lower in the obese subjects than in the control group. Administration of pirenzepine caused a significant reduction of both peak and AUC responses to GHRH in all obese children. Our findings show that administration of a cholinergic antagonist suppresses the already blunted GH response to GHRH in obese children. These and other previous findings indicate the presence of an intact somatostatinergic system in obesity.

Original languageEnglish
Pages (from-to)163-167
Number of pages5
JournalActa Medica Auxologica
Volume25
Issue number3
Publication statusPublished - 1993

Fingerprint

Pirenzepine
Growth Hormone-Releasing Hormone
Growth Hormone
Hormones
Cholinergic Antagonists
Area Under Curve
Obesity
Placebos
Body Weight
Control Groups

Keywords

  • GH
  • GHRH
  • obesity
  • pirenzepine
  • somatostatin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The effect of pirenzepine on the growth hormone response to growth hormone-releasing hormone in obese children. / Loche, S.; Cappa, M.; Faedda, A.; Pintor, C.

In: Acta Medica Auxologica, Vol. 25, No. 3, 1993, p. 163-167.

Research output: Contribution to journalArticle

@article{499299cdbc454c39bb815d01cb5b13fe,
title = "The effect of pirenzepine on the growth hormone response to growth hormone-releasing hormone in obese children",
abstract = "We studied the effect of pirenzepine, a cholinergic antagonist, on the GH response to GH-releasing hormone (GHRH) in 6 obese children (4 males and 2 females) aged 5.3-12.8 years with excess body weight ranging from 42 to 125{\%} for their stature. A GHRH test was also performed in 8 short normal children (5 males and 3 females, age 6.8-11 years) studied as controls. In the obese patients two GHRH (GHRH 1-29, 1 μg/Kg iv) tests were performed 3-7 days apart in random order. Sixty min before the GHRH bolus the patients received placebo or pirenzepine (50 mg po). Mean peak and area under the curve (AUC) responses to GHRH were significantly lower in the obese subjects than in the control group. Administration of pirenzepine caused a significant reduction of both peak and AUC responses to GHRH in all obese children. Our findings show that administration of a cholinergic antagonist suppresses the already blunted GH response to GHRH in obese children. These and other previous findings indicate the presence of an intact somatostatinergic system in obesity.",
keywords = "GH, GHRH, obesity, pirenzepine, somatostatin",
author = "S. Loche and M. Cappa and A. Faedda and C. Pintor",
year = "1993",
language = "English",
volume = "25",
pages = "163--167",
journal = "Acta Medica Auxologica",
issn = "0001-6004",
publisher = "Istituto Auxologico Italiano",
number = "3",

}

TY - JOUR

T1 - The effect of pirenzepine on the growth hormone response to growth hormone-releasing hormone in obese children

AU - Loche, S.

AU - Cappa, M.

AU - Faedda, A.

AU - Pintor, C.

PY - 1993

Y1 - 1993

N2 - We studied the effect of pirenzepine, a cholinergic antagonist, on the GH response to GH-releasing hormone (GHRH) in 6 obese children (4 males and 2 females) aged 5.3-12.8 years with excess body weight ranging from 42 to 125% for their stature. A GHRH test was also performed in 8 short normal children (5 males and 3 females, age 6.8-11 years) studied as controls. In the obese patients two GHRH (GHRH 1-29, 1 μg/Kg iv) tests were performed 3-7 days apart in random order. Sixty min before the GHRH bolus the patients received placebo or pirenzepine (50 mg po). Mean peak and area under the curve (AUC) responses to GHRH were significantly lower in the obese subjects than in the control group. Administration of pirenzepine caused a significant reduction of both peak and AUC responses to GHRH in all obese children. Our findings show that administration of a cholinergic antagonist suppresses the already blunted GH response to GHRH in obese children. These and other previous findings indicate the presence of an intact somatostatinergic system in obesity.

AB - We studied the effect of pirenzepine, a cholinergic antagonist, on the GH response to GH-releasing hormone (GHRH) in 6 obese children (4 males and 2 females) aged 5.3-12.8 years with excess body weight ranging from 42 to 125% for their stature. A GHRH test was also performed in 8 short normal children (5 males and 3 females, age 6.8-11 years) studied as controls. In the obese patients two GHRH (GHRH 1-29, 1 μg/Kg iv) tests were performed 3-7 days apart in random order. Sixty min before the GHRH bolus the patients received placebo or pirenzepine (50 mg po). Mean peak and area under the curve (AUC) responses to GHRH were significantly lower in the obese subjects than in the control group. Administration of pirenzepine caused a significant reduction of both peak and AUC responses to GHRH in all obese children. Our findings show that administration of a cholinergic antagonist suppresses the already blunted GH response to GHRH in obese children. These and other previous findings indicate the presence of an intact somatostatinergic system in obesity.

KW - GH

KW - GHRH

KW - obesity

KW - pirenzepine

KW - somatostatin

UR - http://www.scopus.com/inward/record.url?scp=0027713273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027713273&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 163

EP - 167

JO - Acta Medica Auxologica

JF - Acta Medica Auxologica

SN - 0001-6004

IS - 3

ER -